CY1114634T1 - SP35 OPTIONS AND USES OF THESE - Google Patents
SP35 OPTIONS AND USES OF THESEInfo
- Publication number
- CY1114634T1 CY1114634T1 CY20131101031T CY131101031T CY1114634T1 CY 1114634 T1 CY1114634 T1 CY 1114634T1 CY 20131101031 T CY20131101031 T CY 20131101031T CY 131101031 T CY131101031 T CY 131101031T CY 1114634 T1 CY1114634 T1 CY 1114634T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- endogenous
- oligodendrocytes
- vertebrate
- treatment
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ενδογενής SΡ35 είναι ένας αρνητικός ρυθμιστής για νευρωνική επιβίωση, επαναδημιουργία άξονα, διαφοροποίηση και μυελίνωση ολιγοδενδροκυττάρου (αρνητικός ρυθμιστής). Μόρια που αναστέλλουν λειτουργία ενδογενούς SΡ35 όπως αντι-SΡ35 αντισώματα μπορεί να χρησιμοποιηθούν ως θεραπευτικές ουσίες για τη θεραπεία δυσλειτουργίας νευρώνα και ολιγοδενδροκυττάρου. Η παρούσα εφεύρεση παρέχει αντισώματα ειδικά για SΡ35 και μεθόδους χρήσης τέτοιων αντισωμάτων ως ανταγωνιστών λειτουργίας ενδογενούς SΡ35. Η εφεύρεση περαιτέρω παρέχει ειδικά, λαμβανόμενα από υβρίδωμα και συλλογή φάγου, μονοκλωνικά αντισώματα, νουκλεϊνικά οξέα που κωδικοποιούν αυτά τα αντισώματα και φορείς και κύτταρα ξενιστές που περιλαμβάνουν αυτά τα αντισώματα. Η εφεύρεση περαιτέρω παρέχει μεθόδους προαγωγής, επιβίωσης και μυελίνωσης ολιγοδενδροκυττάρου σε ένα σπονδυλωτό, που περιλαμβάνουν χορήγηση σε ένα σπονδυλωτό που έχει ανάγκη μιας τέτοιας θεραπείας μιας αποτελεσματικής ποσότητας ενός αντι-SΡ35 αντισώματος.Endogenous SP35 is a negative regulator for neuronal survival, axon regeneration, differentiation and myelogenesis of oligodendrocytes (negative regulator). Molecules that inhibit endogenous SP35 function such as anti-SP35 antibodies can be used as therapeutic agents for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for SP35 and methods of using such antibodies as functional antagonists of endogenous SP35. The invention further provides, in particular, derived from hybridoma and phage collection, monoclonal antibodies, nucleic acids encoding these antibodies, and host vectors and cells comprising these antibodies. The invention further provides methods for promoting, survival and myelination of oligodendrocytes in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-SP35 antibody.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69733605A | 2005-07-08 | 2005-07-08 | |
US77190006A | 2006-02-10 | 2006-02-10 | |
US81452206A | 2006-06-19 | 2006-06-19 | |
EP06786428.0A EP1904104B1 (en) | 2005-07-08 | 2006-07-07 | Sp35 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114634T1 true CY1114634T1 (en) | 2016-10-05 |
Family
ID=58448824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101031T CY1114634T1 (en) | 2005-07-08 | 2013-11-21 | SP35 OPTIONS AND USES OF THESE |
Country Status (1)
Country | Link |
---|---|
CY (1) | CY1114634T1 (en) |
-
2013
- 2013-11-21 CY CY20131101031T patent/CY1114634T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120285T1 (en) | Sp35 antibodies and their uses | |
PH12014500347A1 (en) | Sp35 antibodies and uses thereof | |
WO2010005570A3 (en) | Compositions comprising antibodies to lingo or fragments thereof | |
EA200801509A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7 | |
EA200800229A1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST LIGAND-1 PROGRAMMED CELL DECLINATION (PD-L1) | |
JOP20190017B1 (en) | Human cgrp receptor binding antibodies | |
NO346167B1 (en) | Humanized, glycome engineered Type II anti-CD20 antibody and use thereof, as well as host cell and pharmaceutical composition | |
EA200800953A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO CD70 | |
SG170080A1 (en) | Human monoclonal antibodies to o8e | |
DE602005027399D1 (en) | FOR HUMAN MATRIPTASE SPECIFIC TIE PROTEINS | |
CO6180445A2 (en) | ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE | |
WO2007039818A8 (en) | Antigen binding molecules having modified fc regions and altered binding to fc receptors | |
EA200800094A1 (en) | ANTIBODIES CD19 AND THEIR USE | |
ATE492563T1 (en) | COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13 | |
CU23719A3 (en) | ANTIBODY AND IMMUNOCATE WITH NEUTRALIZING ACTIVITY OF RABIA VIRUS, NUCLEIC ACID MOLECULE AND VECTOR | |
ATE482234T1 (en) | ANTIBODIES TO KDR, THEIR PRODUCTION AND USES | |
AR047729A1 (en) | THERAPEUTIC ANTIBODIES THAT BIND APOLIPOPROTEIN E (APOE) | |
RU2012101485A (en) | BESPECIFIC FOUR-PRINCIPAL ANTIGEN-BINDING PROTEINS | |
NZ590991A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
EA200901436A1 (en) | Antigen-binding proteins that bind PAR-2 | |
EA200401453A1 (en) | MOLECULES OF CELLULAR RECOGNITION ON CELLULAR SURFACE CONTAINING IMMUNOGLOBULIN DOMAIN | |
ATE535546T1 (en) | HUMAN MONOCLONAL ANTIBODIES THAT BIND SPECIFICALLY TO IFG-II | |
CY1114634T1 (en) | SP35 OPTIONS AND USES OF THESE | |
ATE336501T1 (en) | CHI-CONOTOXIN PEPTIDES AS INHIBITORS OF NEURONAL AMINE TRANSPORTERS | |
ATE466870T1 (en) | PEPTIDES AND THEIR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES |